Measurements of adiposity as clinical biomarkers for first-line bevacizumab-based chemotherapy in epithelial ovarian cancer. [electronic resource]
Producer: 20140513Description: 11-5 p. digitalISSN:- 1095-6859
- Adiposity
- Angiogenesis Inhibitors -- therapeutic use
- Antibodies, Monoclonal, Humanized -- therapeutic use
- Antineoplastic Combined Chemotherapy Protocols -- therapeutic use
- Bevacizumab
- Body Mass Index
- Carboplatin -- administration & dosage
- Carcinoma, Ovarian Epithelial
- Female
- Humans
- Intra-Abdominal Fat -- diagnostic imaging
- Middle Aged
- Multivariate Analysis
- Neoplasms, Glandular and Epithelial -- blood
- Obesity -- blood
- Ovarian Neoplasms -- blood
- Overweight -- blood
- Paclitaxel -- administration & dosage
- Pilot Projects
- Prognosis
- Proportional Hazards Models
- Retrospective Studies
- Subcutaneous Fat -- diagnostic imaging
- Tomography, X-Ray Computed
- Treatment Outcome
- Vascular Endothelial Growth Factor A -- blood
No physical items for this record
Publication Type: Comparative Study; Journal Article; Observational Study
There are no comments on this title.
Log in to your account to post a comment.